Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
09 Aprile 2024 - 2:00PM
Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage
biotechnology company developing first-in-classi targeted and
immune-mediated therapeutics to fight cancer, today announced that
collaborators at the Beth Israel Deaconess Medical Center (BIDMC)
at Havard Medical presented preclinical data at the American
Association for Cancer Research (AACR) Annual Meeting demonstrating
that TPST-1120 reduces kidney cancer (RCC) growth as a monotherapy,
while also showing increased inhibition when combined with
frontline chemotherapy and immunotherapy. These new data further
support the clinical benefit observed in the TPST-1120 Phase 1 data
presented in an oral presentation at ASCO 2022.
“Preclinical data presented at AACR further
demonstrate that TPST-1120 has the potential to positively
transform the tumor microenvironment and expand the activity of
anti-tumor immunity in kidney cancer,” said Sam Whiting, M.D.,
Ph.D., chief medical officer and head of R&D at Tempest. “The
expanding positive preclinical and clinical findings of TPST-1120
reinforce our excitement for this program and support the next
phase of clinical development into a pivotal HCC study and the
potential to expand into RCC and multiple other cancer types.”
Preclinical data presented at AACR showed that
TPST-1120 increases infiltrating cytotoxic CD8+ T cells in the
tumor microenvironment, consistent with modulation of the tumor
microenvironment to a more immune responsive environment that
allows for the influx of tumor specific CD8+ T cells.
In preclinical models of renal cell carcinoma
(RCC), treatment with TPST-1120 reduced tumor growth by 52%-56% as
monotherapy. Additional improvement in anti-cancer activity was
demonstrated in combination treatment with standard first-line RCC
cabozantinib or anti-PD1 therapy, where tumor inhibition was 81%
and 74%, respectively.
These data reinforce previously reported Phase 1
clinical data where objective responses were observed in patients
with late line, immune refractory RCC treated with TPST-1120 and
the immune therapy, nivolumab, and complement the positive Phase
1b/2 data reported in October 2023 from a global randomized study
of TPST-1120 in combination with atezolizumab and bevacizumab in
first-line patients with advanced HCC, which showed clinical
superiority of the TPST-1120 arm over the control arm across
multiple study endpoints and relevant biomarker-defined patient
subpopulations.
About TPST-1120
TPST-1120 is an oral, small molecule, selective
PPAR⍺ antagonist. Tempest’s data suggest that TPST-1120 treats
cancer by targeting tumor cells directly and by modulating immune
suppressive cells and angiogenesis in the tumor microenvironment.
In an ongoing global randomized phase 1b/2 study of TPST-1120 in
combination with atezolizumab and bevacizumab in first-line
patients with advanced HCC, the TPST-1120 arm showed clinical
superiority across multiple study endpoints when compared to
atezolizumab and bevacizumab alone, the standard of care. These
randomized data were supported by positive results observed in the
Phase 1 clinical trial in patients with heavily pretreated advanced
solid tumors. TPST-1120 is wholly-owned by
Tempest.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage
biotechnology company advancing a diverse portfolio of small
molecule product candidates containing tumor-targeted and/or
immune-mediated mechanisms with the potential to treat a wide range
of tumors. The company’s novel programs range from early research
to later-stage investigation in a randomized global study in
first-line cancer patients. Tempest is headquartered in Brisbane,
California. More information about Tempest can be found on the
company’s website at www.tempesttx.com.
Forward-Looking Statements
This press release contains forward-looking
statements (including within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and Section 27A of the
Securities Act of 1933, as amended (the “Securities Act”))
concerning Tempest Therapeutics, Inc. These statements may discuss
goals, intentions, and expectations as to future plans, trends,
events, results of operations or financial condition, or otherwise,
based on current beliefs of the management of Tempest Therapeutics,
as well as assumptions made by, and information currently available
to, management of Tempest Therapeutics. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as “may,” “will,” “should,” “would,” “could”, “expect,”
“anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,”
“intend,” and other similar expressions. All statements that are
not historical facts are forward-looking statements, including any
statements regarding: the design, initiation, progress, timing,
scope and results of clinical trials; anticipated therapeutic
benefit and regulatory development of the Company’s product
candidates; the Company’s ability to deliver on potential
value-creating milestones; the Company’s ability to advance into a
late-stage clinical company; and the Company’s ability to achieve
its operational plans. Forward-looking statements are based on
information available to Tempest Therapeutics as of the date hereof
and are not guarantees of future performance. Any factors may cause
differences between current expectations and actual results,
including unexpected safety or efficacy data observed during
preclinical or clinical trials; clinical trial site activation or
enrollment rates that are lower than expected; changes in expected
or existing competition; changes in the regulatory environment; and
unexpected litigation or other disputes. Other factors that may
cause actual results to differ from those expressed or implied are
discussed in greater detail in the Form 10-K filed by Tempest
Therapeutics with the Securities and Exchange Commission on March
19, 2024 and other documents filed by the Company from time to time
with the Securities and Exchange Commission. Except as required by
applicable law, Tempest Therapeutics undertakes no obligation to
revise or update any forward-looking statement, or to make any
other forward-looking statements, whether as a result of new
information, future events or otherwise. These forward-looking
statements should not be relied upon as representing Tempest
Therapeutics’ views as of any date subsequent to the date of this
press release and should not be relied upon as a prediction of
future events. In light of the foregoing, investors are urged not
to rely on any forward-looking statement in reaching any conclusion
or making any investment decision about any securities of Tempest
Therapeutics.
Investor & Media Contacts
Sylvia WheelerWheelhouse Life Science
Advisorsswheeler@wheelhouselsa.com
Aljanae Reynolds Wheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Grafico Azioni Tempest Therpeutics (NASDAQ:TPST)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Tempest Therpeutics (NASDAQ:TPST)
Storico
Da Gen 2024 a Gen 2025